The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
Official Title: A Phase II Study of Oral LBH589 in Adult Patients With Cutaneous T-Cell Lymphoma Who Are Intolerant to or Have Progressed on or After Prior HDAC Inhibitor
Study ID: NCT00490776
Brief Summary: This study evaluated the safety and efficacy of LBH589B in adult participants with refractory/resistant Cutaneous T-Cell Lymphoma and prior Histone Deacetylase (HDAC) inhibitor therapy.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Alabama at Birmingham/ The Kirklin Clinic, Birmingham, Alabama, United States
UCLA Medical Center School of Medicine/ Dpt of Hematology-Oncology, Los Angeles, California, United States
University of Colorado Health Sciences Center/Anschutz Cancer Pavillion, Aurora, Colorado, United States
Florida Academic Dermatology Centers, Miami, Florida, United States
Medical College of Georgia, Augusta, Georgia, United States
Rush Presbyterian Hospital/St. Luke's Medical Center, Chicago, Illinois, United States
St. Louis University Cancer Cennter, Saint Louis, Missouri, United States
Nebraska Medical Center, Omaha, Nebraska, United States
Our Lady of Mercy Medical Center/Comprehensive Cancer Center, Bronx, New York, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
NYU Clinical Cancer Center, New York, New York, United States
Wake University Health Sciences, Winston-Salem, North Carolina, United States
University of Oklahoma-Tulsa, Tulsa, Oklahoma, United States
Craig Okada, Portland, Oregon, United States
University of Pittsburg Medical Center, Pittsburgh, Pennsylvania, United States
The Jones Clinic, Germantown, Tennessee, United States
MD Anderson Cancer Center/University of Texas, Houston, Texas, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR